Key terms
About ONCT
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ONCT news
Mar 08
4:43pm ET
Oncternal Therapeutics files $250M mixed securities shelf
Mar 08
8:50am ET
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Mar 07
4:06pm ET
Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)
Feb 13
7:37am ET
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Feb 01
9:02am ET
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
Jan 08
9:21am ET
Oncternal enrolls patients into third dosing cohort of Phase 1/2 trial
Jan 05
7:50pm ET
Oncternal Therapeutics trading halted, news pending
Jan 04
9:05am ET
Oncternal Therapeutics to effect 1-for-20 reverse stock split
Jan 02
9:07am ET
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
Dec 27
6:20am ET
Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Oncternal Therapeutics (ONCT)
Dec 26
9:03am ET
Oncternal Therapeutics provides update on Phase 1/2 study of lymphoma candidate
No recent news articles are available for ONCT
No recent press releases are available for ONCT
ONCT Financials
Key terms
Ad Feedback
ONCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ONCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range